Abstract：
BACKGROUND: Since the early 2000s, acellular dermal matrix has been a popular adjunct to prepectoral breast reconstruction to enhance outcomes.
OBJECTIVE: The aim of this study was to investigate the differences in the postoperative course of 2 standard acellular dermal matrix products, AlloDerm SELECT Ready To Use and DermACELL.
METHODS: A prospective, patient-blind study of patients undergoing bilateral nipple and/or skin-sparing mastectomies with either tissue expander or silicone implant insertion between 2019 and 2022 were selected for this study. The study design used patients as their own controls between 2 products randomly assigned to the left or right breast. Outcomes between the products included average time for drain removal, infection rate, seroma rate, and incorporation rates.
RESULTS: The prospective clinical data of 55 patients (110 breasts) were recorded for 90 days. There were no significant differences between drain removal time, average drain output, or seroma aspiration amount. A higher percentage of seromas was recorded in the breasts with AlloDerm (30.91%) compared with breasts containing DermACELL (14.55%, P < .05), and a statistically significant difference between the incorporation rates of AlloDerm (93.4%) and DermACELL (99.8%, P < .05) was observed.
CONCLUSIONS: Irrespective of patient demographic disparities, both products had a 94.55% success rate for reconstruction outcomes. AlloDerm was determined to have a higher incidence of seromas as a postoperative complication and a trend to lower incorporation.
METHODS:
OBJECTIVE: The aim of this study was to investigate the differences in the postoperative course of 2 standard acellular dermal matrix products, AlloDerm SELECT Ready To Use and DermACELL.
METHODS: A prospective, patient-blind study of patients undergoing bilateral nipple and/or skin-sparing mastectomies with either tissue expander or silicone implant insertion between 2019 and 2022 were selected for this study. The study design used patients as their own controls between 2 products randomly assigned to the left or right breast. Outcomes between the products included average time for drain removal, infection rate, seroma rate, and incorporation rates.
RESULTS: The prospective clinical data of 55 patients (110 breasts) were recorded for 90 days. There were no significant differences between drain removal time, average drain output, or seroma aspiration amount. A higher percentage of seromas was recorded in the breasts with AlloDerm (30.91%) compared with breasts containing DermACELL (14.55%, P < .05), and a statistically significant difference between the incorporation rates of AlloDerm (93.4%) and DermACELL (99.8%, P < .05) was observed.
CONCLUSIONS: Irrespective of patient demographic disparities, both products had a 94.55% success rate for reconstruction outcomes. AlloDerm was determined to have a higher incidence of seromas as a postoperative complication and a trend to lower incorporation.
METHODS:
摘要：
背景：自2000年代初以来，脱细胞真皮基质已成为胸前乳房重建的常用辅助手段，可提高预后。
目的：本研究调查了两个标准脱细胞真皮基质公司在术后过程中的差异，Alloderm选择准备使用和Dermacell。
方法：前瞻性，本研究选择了在2019年至2022年期间接受双侧乳头和/或保留皮肤的乳房切除术并插入组织扩张器或硅胶植入物的患者的盲法研究.研究设计使用患者作为自己的对照，在随机分配到左或右乳房的两种产品之间。品牌之间的结果包括排水去除的平均时间，感染率,血清肿率，和注册率。
结果：记录55例患者（110例乳房）90天的前瞻性临床数据。排水管去除时间之间没有显着差异，平均漏极输出，或血清肿抽吸量。与含有DermACELL的乳房（14.55％，p<0.05)，AlloDerm（93.4％）和DermACELL（99.8％，观察到p<0.05)。
结论：不考虑患者的人口统计学差异，两种产品的重建结果成功率均为94.55%.确定AlloDerm作为术后并发症的血清瘤发生率较高，并且有降低合并的趋势。
目的：本研究调查了两个标准脱细胞真皮基质公司在术后过程中的差异，Alloderm选择准备使用和Dermacell。
方法：前瞻性，本研究选择了在2019年至2022年期间接受双侧乳头和/或保留皮肤的乳房切除术并插入组织扩张器或硅胶植入物的患者的盲法研究.研究设计使用患者作为自己的对照，在随机分配到左或右乳房的两种产品之间。品牌之间的结果包括排水去除的平均时间，感染率,血清肿率，和注册率。
结果：记录55例患者（110例乳房）90天的前瞻性临床数据。排水管去除时间之间没有显着差异，平均漏极输出，或血清肿抽吸量。与含有DermACELL的乳房（14.55％，p<0.05)，AlloDerm（93.4％）和DermACELL（99.8％，观察到p<0.05)。
结论：不考虑患者的人口统计学差异，两种产品的重建结果成功率均为94.55%.确定AlloDerm作为术后并发症的血清瘤发生率较高，并且有降低合并的趋势。
